Regulation of Rad51 promoter

Cell Cycle

Volumn 13, Issue 13, 2014, Pages 2038-2045

  Hine, Christopher M ^b   Li, Hongjie ^a   Xie, Li ^a   Mao, Zhiyong ^c   Seluanov, Andrei ^a   Gorbunova, Vera ^a  

^a UNIVERSITY OF ROCHESTER   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c TONGJI UNIVERSITY   (China)

Author keywords

Cancer; DNA repair; EGR1; P53; Rad51 promoter; Therapy resistance

Indexed keywords

EARLY GROWTH RESPONSE FACTOR 1; PROTEIN P53; RAD51 PROTEIN; RAS PROTEIN; VIRUS LARGE T ANTIGEN; VIRUS SMALL T ANTIGEN; NAB1 PROTEIN, HUMAN; REPRESSOR PROTEIN; VIRUS T ANTIGEN;

ARTICLE; DOWN REGULATION; EXON; FIBROBLAST; GENE CONTROL; GENE MUTATION; HUMAN; HUMAN CELL; INTRON; MALIGNANT TRANSFORMATION; PROMOTER REGION; REPORTER GENE; UPREGULATION; CELL LINE; CELL TRANSFORMATION; GENETICS; METABOLISM; TUMOR CELL LINE;

ANTIGENS, POLYOMAVIRUS TRANSFORMING; CELL LINE; CELL LINE, TUMOR; CELL TRANSFORMATION, NEOPLASTIC; DOWN-REGULATION; FIBROBLASTS; HUMANS; PROMOTER REGIONS, GENETIC; RAD51 RECOMBINASE; RAS PROTEINS; REPRESSOR PROTEINS; UP-REGULATION;

EID: 84903784926     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.29016     Document Type: Article

References (43)

1. Kawasaki H, Altieri DC, Lu CD, Toyoda M, Tenjo T, Tanigawa N. Inhibition of apoptosis by survivin predicts shorter survival rates in colorectal cancer. Cancer Res 1998; 58:5071-4; PMID:9823313
2. Ohta T, Iijima K, Miyamoto M, Nakahara I, Tanaka H, Ohtsuji M, Suzuki T, Kobayashi A, Yokota J, Sakiyama T, et al. Loss of Keap1 function activates Nrf2 and provides advantages for lung cancer cell growth. Cancer Res 2008; 68:1303-9; PMID:18316592; http://dx.doi.org/10.1158/0008-5472.CAN-07-5003
3. Shibata T, Kokubu A, Saito S, Narisawa-Saito M, Sasaki H, Aoyagi K, Yoshimatsu Y, Tachimori Y, Kushima R, Kiyono T, et al. NRF2 mutation confers malignant potential and resistance to chemoradiation therapy in advanced esophageal squamous cancer. Neoplasia 2011; 13:864-73; PMID:21969819
4. Helleday T. Homologous recombination in cancer development, treatment and development of drug resistance. Carcinogenesis 2010; 31:955-60; PMID:20351092; http://dx.doi.org/10.1093/carcin/bgq064
5. Helleday T, Petermann E, Lundin C, Hodgson B, Sharma RA. DNA repair pathways as targets for cancer therapy. Nat Rev Cancer 2008; 8:193-204; PMID:18256616; http://dx.doi.org/10.1038/nrc2342
6. Treré D, Ceccarelli C, Migaldi M, Santini D, Taffurelli M, Tosti E, Chieco P, Derenzini M. Cell proliferation in breast cancer is a major determinant of clinical outcome in node-positive but not in node-negative patients. Appl Immunohistochem Mol Morphol 2006; 14:314-23; PMID:16932023; http://dx.doi.org/10.1097/00129039-200609000-00010
7. Wu X, Roth JA, Zhao H, Luo S, Zheng YL, Chiang S, Spitz MR. Cell cycle checkpoints, DNA damage/repair, and lung cancer risk. Cancer Res 2005; 65:349-57; PMID:15665313
8. Petermann E, Orta ML, Issaeva N, Schultz N, Helleday T. Hydroxyurea-stalled replication forks become progressively inactivated and require two different RAD51-mediated pathways for restart and repair. Mol Cell 2010; 37:492-502; PMID:20188668; http://dx.doi.org/10.1016/j.molcel.2010.01.021
9. Schild D, Wiese C. Overexpression of RAD51 suppresses recombination defects: a possible mechanism to reverse genomic instability. Nucleic Acids Res 2010; 38:1061-70; PMID:19942681; http://dx.doi.org/10.1093/nar/gkp1063
10. Hine CM, Seluanov A, Gorbunova V. Use of the Rad51 promoter for targeted anti-cancer therapy. Proc Natl Acad Sci U S A 2008; 105:20810-5; PMID:19106292; http://dx.doi.org/10.1073/pnas.0807990106
11. Richardson C, Stark JM, Ommundsen M, Jasin M. Rad51 overexpression promotes alternative doublestrand break repair pathways and genome instability. Oncogene 2004; 23:546-53; PMID:14724582; http://dx.doi.org/10.1038/sj.onc. 1207098
12. Raderschall E, Stout K, Freier S, Suckow V, Schweiger S, Haaf T. Elevated levels of Rad51 recombination protein in tumor cells. Cancer Res 2002; 62:219-25; PMID:11782381
13. Hannay JA, Liu J, Zhu QS, Bolshakov SV, Li L, Pisters PW, Lazar AJ, Yu D, Pollock RE, Lev D. Rad51 overexpression contributes to chemoresistance in human soft tissue sarcoma cells: a role for p53/activator protein 2 transcriptional regulation. Mol Cancer Ther 2007; 6:1650-60; PMID:17513613; http://dx.doi.org/ 10.1158/1535-7163.MCT-06-0636
14. Maacke H, Jost K, Opitz S, Miska S, Yuan Y, Hasselbach L, Lüttges J, Kalthoff H, Stürzbecher HW. DNA repair and recombination factor Rad51 is over-expressed in human pancreatic adenocarcinoma. Oncogene 2000; 19:2791-5; PMID:10851081; http://dx.doi.org/10.1038/sj.onc.1203578
15. Maacke H, Opitz S, Jost K, Hamdorf W, Henning W, Krüger S, Feller AC, Lopens A, Diedrich K, Schwinger E, et al. Over-expression of wild-type Rad51 correlates with histological grading of invasive ductal breast cancer. Int J Cancer 2000; 88:907-13; PMID:11093813; http://dx.doi.org/10.1002/1097- 0215(20001215)88:6<907::AID-IJC11>3.0.CO;2-4
16. Collis SJ, Tighe A, Scott SD, Roberts SA, Hendry JH, Margison GP. Ribozyme minigene-mediated RAD51 down-regulation increases radiosensitivity of human prostate cancer cells. Nucleic Acids Res 2001; 29:1534-8; PMID:11266555; http://dx.doi.org/10.1093/nar/29.7.1534
17. Kauffmann A, Rosselli F, Lazar V, Winnepenninckx V, Mansuet-Lupo A, Dessen P, van den Oord JJ, Spatz A, Sarasin A. High expression of DNA repair pathways is associated with metastasis in melanoma patients. Oncogene 2008; 27:565-73; PMID:17891185; http://dx.doi.org/10.1038/sj.onc.1210700
18. Mitra A, Jameson C, Barbachano Y, Sanchez L, Kote-Jarai Z, Peock S, Sodha N, Bancroft E, Fletcher A, Cooper C, et al.; IMPACT Steering Committee and IMPACT and EMBRACE Collaborators. Overexpression of RAD51 occurs in aggressive prostatic cancer. Histopathology 2009; 55:696-704; PMID:20002770; http://dx.doi.org/10.1111/j.1365-2559.2009.03448.x
19. Barbano R, Copetti M, Perrone G, Pazienza V, Muscarella LA, Balsamo T, Storlazzi CT, Ripoli M, Rinaldi M, Valori VM, et al. High RAD51 mRNA expression characterize estrogen receptor-positive/progesteron receptor-negative breast cancer and is associated with patient's outcome. Int J Cancer 2011; 129:536-45; PMID:21064098; http://dx.doi.org/10.1002/ijc.25736
20. Qiao GB, Wu YL, Yang XN, Zhong WZ, Xie D, Guan XY, Fischer D, Kolberg HC, Kruger S, Stuerzbecher HW. High-level expression of Rad51 is an independent prognostic marker of survival in non-small-cell lung cancer patients. Br J Cancer 2005; 93:137-43; PMID:15956972; http://dx.doi.org/10.1038/sj.bjc.6602665
21. Nogueira A, Catarino R, Coelho A, Araújo A, Gomes M, Medeiros R. Influence of DNA repair RAD51 gene variants in overall survival of non-small cell lung cancer patients treated with first line chemotherapy. Cancer Chemother Pharmacol 2010; 66:501-6; PMID:19960343
22. Arias-Lopez C, Lazaro-Trueba I, Kerr P, Lord CJ, Dexter T, Iravani M, Ashworth A, Silva A. p53 modulates homologous recombination by transcriptional regulation of the RAD51 gene. EMBO Rep 2006; 7:219-24; PMID:16322760; http://dx.doi.org/10.1038/sj.embor.7400587
23. Fong V, Osterbur M, Capella C, Kim YE, Hine C, Gorbunova V, Seluanov A, Dewhurst S. Adenoviral vector driven by a minimal Rad51 promoter is selective for p53-deficient tumor cells. PLoS One 2011; 6:e28714; PMID:22174876; http://dx.doi. org/10.1371/journal.pone.0028714
24. Hine CM, Seluanov A, Gorbunova V. Rad51 Promoter-Targeted Gene Therapy Is Effective for In Vivo Visualization and Treatment of Cancer. Mol Ther 2012; 20:347-55; PMID:22008909; http://dx.doi.org/10.1038/mt.2011.215
25. Hasselbach L, Haase S, Fischer D, Kolberg HC, Stürzbecher HW. Characterisation of the promoter region of the human DNA-repair gene Rad51. Eur J Gynaecol Oncol 2005; 26:589-98; PMID:16398215
26. Hollstein M, Sidransky D, Vogelstein B, Harris CC. p53 mutations in human cancers. Science 1991; 253:49-53; PMID:1905840; http://dx.doi.org/10.1126/ science.1905840
27. Yang SZ, Eltoum IA, Abdulkadir SA. Enhanced EGR1 activity promotes the growth of prostate cancer cells in an androgen-depleted environment. J Cell Biochem 2006; 97:1292-9; PMID:16552752; http://dx.doi.org/10.1002/jcb.20736
28. Hahn WC, Counter CM, Lundberg AS, Beijersbergen RL, Brooks MW, Weinberg RA. Creation of human tumour cells with defined genetic elements. Nature 1999; 400:464-8; PMID:10440377; http://dx.doi.org/10.1038/22780
29. Hahn WC, Weinberg RA. Rules for making human tumor cells. N Engl J Med 2002; 347:1593-603; PMID:12432047; http://dx.doi.org/10.1056/NEJMra021902
30. Rangarajan A, Hong SJ, Gifford A, Weinberg RA. Species- and cell type-specific requirements for cellular transformation. Cancer Cell 2004; 6:171-83; PMID:15324700; http://dx.doi.org/10.1016/j.ccr.2004.07.009
31. Virolle T, Krones-Herzig A, Baron V, De Gregorio G, Adamson ED, Mercola D. Egr1 promotes growth and survival of prostate cancer cells. Identification of novel Egr1 target genes. J Biol Chem 2003; 278:11802-10; PMID:12556466; http://dx.doi.org/10.1074/jbc.M210279200
32. Ahuja D, Sáenz-Robles MT, Pipas JM. SV40 large T antigen targets multiple cellular pathways to elicit cellular transformation. Oncogene 2005; 24:7729-45; PMID:16299533; http://dx.doi.org/10.1038/sj.onc.1209046
33. Shuda M, Kwun HJ, Feng H, Chang Y, Moore PS. Human Merkel cell polyomavirus small T antigen is an oncoprotein targeting the 4E-BP1 translation regulator. J Clin Invest 2011; 121:3623-34; PMID:21841310; http://dx.doi.org/10. 1172/JCI46323
34. White MA, Nicolette C, Minden A, Polverino A, Van Aelst L, Karin M, Wigler MH. Multiple Ras functions can contribute to mammalian cell transformation. Cell 1995; 80:533-41; PMID:7867061; http://dx.doi.org/10.1016/ 0092-8674(95)90507-3
35. Bindra RS, Glazer PM. Repression of RAD51 gene expression by E2F4/p130 complexes in hypoxia. Oncogene 2007; 26:2048-57; PMID:17001309; http://dx.doi.org/10.1038/sj.onc.1210001
36. Popov B, Chang LS, Serikov V. Cell cycle-related transformation of the E2F4-p130 repressor complex. Biochem Biophys Res Commun 2005; 336:762-9; PMID:16153605; http://dx.doi.org/10.1016/j.bbrc.2005.08.163
37. Slupianek A, Hoser G, Majsterek I, Bronisz A, Malecki M, Blasiak J, Fishel R, Skorski T. Fusion tyrosine kinases induce drug resistance by stimulation of homology-dependent recombination repair, prolongation of G(2)/M phase, and protection from apoptosis. Mol Cell Biol 2002; 22:4189-201; PMID:12024032; http://dx.doi.org/10.1128/MCB.22.12.4189-4201.2002
38. Slupianek A, Schmutte C, Tombline G, Nieborowska-Skorska M, Hoser G, Nowicki MO, Pierce AJ, Fishel R, Skorski T. BCR/ABL regulates mammalian RecA homologs, resulting in drug resistance. Mol Cell 2001; 8:795-806; PMID:11684015; http://dx.doi.org/10.1016/S1097-2765(01)00357-4
39. Schmutte C, Tombline G, Rhiem K, Sadoff MM, Schmutzler R, von Deimling A, Fishel R. Characterization of the human Rad51 genomic locus and examination of tumors with 15q14-15 loss of heterozygosity (LOH). Cancer Res 1999; 59:4564-9; PMID:10493508
40. Yu Y, Kudchodkar SB, Alwine JC. Effects of simian virus 40 large and small tumor antigens on mammalian target of rapamycin signaling: small tumor antigen mediates hypophosphorylation of eIF4E-binding protein 1 late in infection. J Virol 2005; 79:6882-9; PMID:15890927; http://dx.doi.org/10.1128/ JVI.79.11.6882-6889.2005
41. Hayman TJ, Williams ES, Jamal M, Shankavaram UT, Camphausen K, Tofilon PJ. Translation initiation factor eIF4E is a target for tumor cell radiosensitization. Cancer Res 2012; 72:2362-72; PMID:22397984; http://dx.doi.org/10.1158/0008-5472.CAN-12-0329
42. Wu L, Johnson M, Sato M. Transcriptionally targeted gene therapy to detect and treat cancer. Trends Mol Med 2003; 9:421-9; PMID:14557054; http://dx.doi. org/10.1016/j.molmed.2003.08.005
43. Lo HW, Day CP, Hung MC. Cancer-specific gene therapy. Adv Genet 2005; 54:235-55; PMID:16096014; http://dx.doi.org/10.1016/S0065-2660(05)54010-0